Newtopia Reports Second Quarter 2023 Financial Results
- Cash Flow Positive from Operations in May & June, ahead of 2023 plan
- Q2 2023 Gross Margin (non IFRS)1 up 1150 basis points year over year
- Operating Expenses down
$1.3 million (41%) year over year - Quarterly conference call scheduled for
Aug 9, 2023 at5 pm ET
Second Quarter 2023 Financial Highlights (vs. Q2 2022):
- Revenue of
$2.4 million , as compared to$2.5 million . - Gross profit margin1 of 58.5%, as compared to 47.0%.
"Newtopia had a very productive second quarter, as we continued to effectively manage our costs in a challenging macro environment to achieve cash flow positive from operations well ahead of our internal plan," said
Ruby continued, "We anticipate that our recent multi-year contract renewals with large clients will enhance our revenue and profitability in the second half of the year. In addition to growth with existing clients, our pipeline of new business development with risk-bearing entities, including self-insured employers and innovative health plans, remains robust. Not only have we made progress with existing, in-contracting deals, but we've also added opportunities to the contracting queue. Importantly, our clients continue to see high participant engagement and satisfaction with Newtopia, alongside healthy habit change results. Newtopia's position at the forefront of preventing, slowing and reversing chronic disease ideally fits with larger healthcare macro trends including the massive interest and market size for GLP-1 medications for weight loss and the shift by employers and commercial populations towards value based advanced primary care. These trends provide fertile ground for continued expansion. To maintain this positive momentum, we have developed a special committee within our Board of Directors who will be working to explore avenues and partnerships to accelerate our growth. We look forward to sharing our progress along the way."
Second Quarter 2023 Financial Results
Revenue for the three months ended
Non-IFRS gross profit for the second quarter 2023 totaled
Operating expenses2 for the three months ended
The Company ended the second quarter 2023 with approximately
2023 Outlook
Newtopia continues to expect full-year revenue growth in 2023 as compared to the prior year. Newtopia anticipates that the Company is also on a clear path to EBITDA and cash flow positivity within 2023 by continuing to exert strategic expense management. Profitability is anticipated to build throughout the year, with the bottom line improving incrementally each quarter.
Grants of Stock Options
Newtopia further announced today that its Board of Directors has approved the grant of 250,000 stock options to certain tenured employees. The issued options will be at an exercise price of
Conference Call
The Company will host a conference call today at
A replay of the conference call will be available through
About Newtopia
Newtopia is a tech-enabled habit change provider focused on disease prevention and reducing the cost of care for health insurers. As a provider of whole person care, we prevent, reverse and slow the progression of chronic disease while enriching mental health, resilience and overall human performance. Newtopia's programs leverage genetic, social and behavioral insights to create individualized prevention programs with a focus on type 2 diabetes, heart disease, stroke and weight. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. To learn more, visit newtopia.com, LinkedIn or Twitter.
Forward Looking Statements
This news release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable
Should any factor affect Newtopia in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Newtopia does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release, and Newtopia undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
Non-IFRS Financial Measures
The Company's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS"). Management uses certain non-IFRS measures, which are defined in the appropriate sections of this press release, to better assess the Company's underlying performance. These measures are reviewed regularly by management and the Company's Board of Directors in assessing the Company's performance and in making decisions about ongoing operations. In addition, we use certain non-IFRS measures to determine the components of management compensation. We believe that these measures are also used by investors as an indicator of the Company's operating performance. Readers are cautioned that these terms are not recognized IFRS measures and do not have a standardized meaning under IFRS and should not be construed as alternatives to IFRS terms, such as net income.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Key Financial Measures and Schedule of Non-GAAP Reconciliations
Gross Profit Information [1]
Three Months Ended | Six Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
$ | $ | $ | $ | ||||
Revenue | 2,357,034 | 2,531,986 | 5,005,691 | 5,398,700 | |||
Cost of revenue | (1,184,993) | (1,341,941) | (2,460,675) | (2,859,777) | |||
Gross profit | 1,172,041 | 1,190,045 | 2,545,016 | 2,538,923 | |||
Add Amortization of intangible asset | 206,514 | - | 413,028 | - | |||
Non-IFRS adjusted gross profit | 1,378,555 | 1,190,045 | 2,958,044 | 2,538,923 | |||
Gross profit margin | 50 % | 47 % | 51 % | 47 % | |||
Non-IFRS adjusted gross profit margin | 58 % | 47 % | 59 % | 47 % | |||
Reconciliation of Total Operating Expenses to Adjusted Operating Expenses [2]
Three Months Ended | Six Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
$ | $ | $ | $ | ||||
Total expenses | 2,403,354 | 3,421,786 | 5,149,156 | 6,398,357 | |||
Add (Subtract) | |||||||
Share-based compensation | (215,013) | (131,290) | (308,303) | (263,798) | |||
Depreciation of property and equipment | (2,030) | (13,403) | (3,579) | (27,783) | |||
Depreciation of right-of-use asset | - | (46,192) | - | (92,387) | |||
Interest on lease obligations | (8,973) | (20,283) | (21,563) | (43,262) | |||
Interest and accretion expense | (177,728) | (100,431) | (347,423) | (197,721) | |||
Finance charges | (122,318) | (40,437) | (231,966) | (77,547) | |||
Capitalized borrowing costs | - | 38,000 | - | 67,000 | |||
Foreign exchange loss (gain) | (35,821) | 38,497 | (54,093) | 23,464 | |||
Amortization of deferred finance charges | (33,975) | (64,970) | (67,790) | (123,770) | |||
Gain on settlement of related party payable | 7,203 | - | 7,203 | - | |||
Adjusted operating expenses | 1,814,699 | 3,081,277 | 4,121,642 | 5,662,553 | |||
EBITDA [3]
Three Months Ended | Six Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
$ | $ | $ | $ | ||||
Non-IFRS adjusted gross profit | 1,378,555 | 1,190,045 | 2,958,044 | 2,538,923 | |||
Adjusted operating expenses | (1,814,699) | (3,081,277) | (4,121,642) | (5,662,553) | |||
EBITDA | (436,144) | (1,891,232) | (1,163,598) | (3,123,630) | |||
NEWTOPIA INC.
Condensed Interim Statements of Financial Position (Unaudited)
As at
(Expressed in Canadian Dollars)
2023 | 2022 | |||
(Unaudited) | (Audited) | |||
$ | $ | |||
Assets | ||||
Current assets | ||||
Cash | 296,573 | 345,950 | ||
Trade and other receivables | 1,520,374 | 1,557,640 | ||
Contract asset | - | 190,000 | ||
Prepaid expenses and deposits | 259,165 | 205,843 | ||
Inventories | 140,176 | 325,571 | ||
Deferred costs | 37,639 | 76,269 | ||
2,253,927 | 2,701,273 | |||
Property and equipment | 5,572 | 8,052 | ||
Intangible asset | 2,822,335 | 3,235,363 | ||
5,081,834 | 5,944,688 | |||
Liabilities | ||||
Current liabilities | ||||
Trade and other payables | 2,433,354 | 2,584,039 | ||
Credit facility | 4,809,913 | 4,823,545 | ||
Lease obligations | 209,077 | 544,700 | ||
Deferred revenue | 48,185 | 48,185 | ||
Contract liability | 80,100 | - | ||
Debentures | 3,730,523 | 2,409,103 | ||
11,311,152 | 10,409,572 | |||
Debentures | - | 1,068,772 | ||
11,311,152 | 11,478,344 | |||
Equity/Deficit | ||||
Common shares | 48,882,767 | 47,978,992 | ||
Contributed surplus | 13,866,152 | 12,861,449 | ||
Deficit | (68,978,237) | (66,374,097) | ||
(6,229,318) | (5,533,656) | |||
5,081,834 | 5,944,688 |
NEWTOPIA INC.
Condensed Interim Statements of Loss and Comprehensive Loss (Unaudited)
Three and Six Months Ended
(Expressed in Canadian Dollars)
Three Months Ended | Six Months Ended | ||||||
2023 | 2022 | 2023 | 2022 | ||||
$ | $ | $ | $ | ||||
Revenue | 2,357,034 | 2,531,986 | 5,005,691 | 5,398,700 | |||
Cost of revenue | 1,184,993 | 1,341,941 | 2,460,675 | 2,859,777 | |||
Gross profit | 1,172,041 | 1,190,045 | 2,545,016 | 2,538,923 | |||
Operating expenses | |||||||
Technology and development | 522,707 | 844,105 | 1,444,772 | 1,650,400 | |||
Sales and marketing | 351,262 | 868,934 | 777,432 | 1,513,145 | |||
General and administrative | 940,730 | 1,368,238 | 1,899,438 | 2,499,008 | |||
Share-based compensation | 215,013 | 131,290 | 308,303 | 263,798 | |||
Depreciation of property and equipment | 2,030 | 13,403 | 3,579 | 27,783 | |||
Depreciation of right-of-use asset | - | 46,192 | - | 92,387 | |||
2,031,742 | 3,272,162 | 4,433,524 | 6,046,521 | ||||
Other expenses (income) | |||||||
Interest and accretion expense | 177,728 | 100,431 | 347,423 | 197,721 | |||
Interest on lease obligations | 8,973 | 20,283 | 21,563 | 43,262 | |||
Finance charges | 122,318 | 40,437 | 231,966 | 77,547 | |||
Amortization of deferred finance charges | 33,975 | 64,970 | 67,790 | 123,770 | |||
Foreign exchange (gain)/loss | 35,821 | (38,497) | 54,093 | (23,464) | |||
Capitalized borrowing costs | - | (38,000) | - | (67,000) | |||
Gain on settlement of related party payable | (7,203) | - | (7,203) | - | |||
371,612 | 149,624 | 715,632 | 351,836 | ||||
Net loss and comprehensive loss | (1,231,313) | (2,231,741) | (2,604,140) | (3,859,434) | |||
NEWTOPIA INC.
Condensed Interim Statements of Changes in Equity (Deficit) (Unaudited)
Six Months Ended
(Expressed in Canadian Dollars)
Common Shares |
Contributed Surplus | Deficit |
Total | ||
$ | $ | $ | $ | ||
Balance, | 47,978,992 | 12,861,449 | (66,374,097) | (5,533,656) | |
Net loss and comprehensive loss | - | - | (2,604,140) | (2,604,140) | |
Share-based compensation | - | 308,303 | - | 308,303 | |
Settlement of related party payable | - | 132,880 | - | 132,880 | |
930,218 | 537,077 | - | 1,467,295 | ||
Compensation options | (26,443) | 26,443 | - | - | |
Balance, | 48,882,767 | 13,866,152 | (68,978,237) | (6,229,318) | |
Balance, | 45,177,120 | 11,652,200 | (58,673,634) | (1,844,314) | |
Net loss and comprehensive loss | - | - | (3,859,434) | (3,859,434) | |
Share-based compensation | - | 263,798 | - | 263,798 | |
Settlement of related party payable | - | 54,522 | - | 54,522 | |
2,624,495 | 511,839 | - | 3,136,334 | ||
Compensation options issued to brokers | (83,230) | 83,230 | - | - | |
Balance, | 47,718,385 | 12,565,589 | (62,533,068) | (2,249,094) | |
NEWTOPIA INC.
Condensed Interim Statements of Cash Flows (Unaudited)
Six Months Ended
(Expressed in Canadian Dollars)
Six Months Ended | ||||
2023 | 2022 | |||
$ | $ | |||
Cash flows used in operating activities: | ||||
Net loss and comprehensive loss | (2,604,140) | (3,859,434) | ||
Items not involving cash: | ||||
Depreciation of property and equipment | 3,579 | 27,783 | ||
Depreciation of right-of-use asset | - | 92,387 | ||
Amortization of intangible asset | 413,028 | - | ||
Amortization of deferred finance charges | 67,790 | 123,770 | ||
Capitalized borrowing costs | - | (67,000) | ||
Share-based compensation | 308,303 | 263,798 | ||
Interest and accretion expense | 252,648 | 95,921 | ||
Interest on lease obligations | 21,563 | 43,262 | ||
Gain on settlement of related party payable | (7,203) | - | ||
(1,544,432) | (3,279,513) | |||
Net change in non-cash working capital | ||||
Trade and other receivables | 37,266 | 495,162 | ||
Contract asset/liability | 270,100 | (287,034) | ||
Inventories | 185,395 | (145,142) | ||
Prepaid expenses and deposits | (53,322) | (22,023) | ||
Trade and other payables | (10,602) | 538,112 | ||
Deferred revenue | - | (8,065) | ||
(1,115,595) | (2,708,503) | |||
Cash flows used in investing activities: | ||||
Purchase of property and equipment | (1,099) | (3,829) | ||
Intangible asset development costs | - | (898,895) | ||
(1,099) | (902,724) | |||
Cash flows from (used in) financing activities: | ||||
Credit facility withdrawals | 2,864,097 | 5,633,116 | ||
Credit facility repayments | (2,877,729) | (5,074,304) | ||
Credit facility financing costs | (29,160) | (45,931) | ||
Repayment of lease obligations | (357,186) | (187,942) | ||
Proceeds from private placement offerings, net of issuance costs | 1,467,295 | 3,136,334 | ||
1,067,317 | 3,461,273 | |||
Decrease in cash | (49,377) | (149,954) | ||
Cash, beginning of period | 345,950 | 811,584 | ||
Cash, end of period | 296,573 | 661,630 | ||
___________ | |
1 | Gross profit is defined as revenue, which is comprised of onboarding |
2 | Adjusted operating expenses consist of all cash-based technology, sales and marketing and administrative expenses. Adjusted operating expense is not a measure of financial performance under IFRS and should not be considered a substitute for total operating expenses, which we believe to be the most directly comparable IFRS measure. |
3 | EBITDA stands for "earnings before interest, tax, depreciation and amortization". Although a commonly used financial metric, EBITDA is not a measure of financial performance under IFRS and should not be considered a substitute for loss from operations which we believe to be the most directly comparable IFRS measure. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/newtopia-reports-second-quarter-2023-financial-results-301897189.html
SOURCE Newtopia Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Elliott Management Sends Letter to Northern Star Resources Ltd Board of Directors
- i2Cool Launches i2Coating CorroCool, Combining Electricity-Free Cooling with Industrial-Grade Corrosion Protection
- Lewie Expands Retail Distribution Through Hen House Markets in Kansas City
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share